相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR
Soma Ghosh et al.
CELL REPORTS (2021)
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway
Kari J. Kurppa et al.
CANCER CELL (2020)
Cell Cycle Checkpoints Cooperate to Suppress DNA- and RNA-Associated Molecular Pattern Recognition and Anti-Tumor Immune Responses
Jie Chen et al.
CELL REPORTS (2020)
EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer
Ke Gong et al.
NATURE CANCER (2020)
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
A. J. Schoenfeld et al.
ANNALS OF ONCOLOGY (2019)
Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy
Avinash Das Sahu et al.
MOLECULAR SYSTEMS BIOLOGY (2019)
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
Triparna Sen et al.
CANCER DISCOVERY (2019)
Targeting intrinsic RIG-I signaling turns melanoma cells into type I interferon-releasing cellular antitumor vaccines
Sarah Bek et al.
ONCOIMMUNOLOGY (2019)
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J. Mazieres et al.
ANNALS OF ONCOLOGY (2019)
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
K. Hastings et al.
ANNALS OF ONCOLOGY (2019)
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer
Miriam Molina-Arcas et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab
Carlo Genova et al.
JOURNAL OF CLINICAL MEDICINE (2019)
RIG-I activation is critical for responsiveness to checkpoint blockade
Simon Heidegger et al.
SCIENCE IMMUNOLOGY (2019)
EGFR-TKI acquired resistance in lung cancers harboring EGFR mutations in immunocompetent C57BL/6J mice
Hisao Higo et al.
LUNG CANCER (2019)
Adaptive mutability of colorectal cancers in response to targeted therapies
Mariangela Russo et al.
SCIENCE (2019)
The dynamic nature of senescence in cancer
Soyoung Lee et al.
NATURE CELL BIOLOGY (2019)
Senescence-associated reprogramming promotes cancer stemness
Maja Milanovic et al.
NATURE (2018)
Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma
Yong Yu et al.
CANCER CELL (2018)
LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade
Wanqiang Sheng et al.
CELL (2018)
Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8+ T Cells
Jing Li et al.
IMMUNITY (2018)
HMGB2 Loss upon Senescence Entry Disrupts Genomic Organization and Induces CTCF Clustering across Cell Types
Anne Zirkel et al.
MOLECULAR CELL (2018)
Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses
Israel Canadas et al.
NATURE MEDICINE (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer
Caitlin L. Grzeskowiak et al.
NATURE COMMUNICATIONS (2018)
Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment
David L. Elion et al.
Oncotarget (2018)
Therapeutically Active RIG-I Agonist Induces Immunogenic Tumor Cell Killing in Breast Cancers
David L. Elion et al.
CANCER RESEARCH (2018)
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Livnat Jerby-Arnon et al.
CELL (2018)
Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer
Hanghang Zhang et al.
CELL (2018)
NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination
Marcus Ruscetti et al.
SCIENCE (2018)
A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types
Marie-Claire Wagle et al.
NPJ PRECISION ONCOLOGY (2018)
SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants
Meleri Jones et al.
JOURNAL OF MEDICAL VIROLOGY (2017)
CDK4/6 inhibition triggers anti-tumour immunity
Shom Goel et al.
NATURE (2017)
Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition
Matthew J. Hangauer et al.
NATURE (2017)
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
Vasanthi S. Viswanathan et al.
NATURE (2017)
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors
Dennis Plenker et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to Preoperative Trastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer
Vinay Varadan et al.
CLINICAL CANCER RESEARCH (2016)
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
Aaron N. Hata et al.
NATURE MEDICINE (2016)
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Itay Tirosh et al.
SCIENCE (2016)
Discriminating self from non-self in nucleic acid sensing
Martin Schlee et al.
NATURE REVIEWS IMMUNOLOGY (2016)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts
David Roulois et al.
CELL (2015)
Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma
Lawrence N. Kwong et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
Kenneth S. Thress et al.
NATURE MEDICINE (2015)
Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma
Pawel K. Mazur et al.
NATURE MEDICINE (2015)
Robust enumeration of cell subsets from tissue expression profiles
Aaron M. Newman et al.
NATURE METHODS (2015)
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells
Cole Trapnell et al.
NATURE BIOTECHNOLOGY (2014)
Oncogene Mimicry as a Mechanism of Primary Resistance to BRAF Inhibitors
Martin L. Sos et al.
CELL REPORTS (2014)
Therapeutic Efficacy of Bifunctional siRNA Combining TGF-β1 Silencing with RIG-I Activation in Pancreatic Cancer
Jonathan Ellermeier et al.
CANCER RESEARCH (2013)
Synthetic lethal metabolic targeting of cellular senescence in cancer therapy
Jan R. Doerr et al.
NATURE (2013)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sreenath V. Sharma et al.
CELL (2010)
Decoding Cell Death Signals in Inflammation and Immunity
Laurence Zitvogel et al.
CELL (2010)
Recognition of 5′ Triphosphate by RIG-I Helicase Requires Short Blunt Double-Stranded RNA as Contained in Panhandle of Negative-Strand Virus
Martin Schlee et al.
IMMUNITY (2009)
Genetic Predictors of MEK Dependence in Non-Small Cell Lung Cancer
Christine A. Pratilas et al.
CANCER RESEARCH (2008)
Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP-C promoter
Kadoaki Ohashi et al.
CANCER SCIENCE (2008)
Module map of stem cell genes guides creation of epithelial cancer stem cells
David J. Wong et al.
CELL STEM CELL (2008)
5′-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma
Hendrik Poeck et al.
NATURE MEDICINE (2008)
分享论文
